Meridiem Capital Partners LP Buys Shares of 68,788 Waters Corporation $WAT

Meridiem Capital Partners LP purchased a new stake in shares of Waters Corporation (NYSE:WAT) during the 3rd quarter, HoldingsChannel.com reports. The firm purchased 68,788 shares of the medical instruments supplier’s stock, valued at approximately $20,623,000. Waters makes up 1.3% of Meridiem Capital Partners LP’s portfolio, making the stock its 29th largest holding.

A number of other large investors also recently modified their holdings of the company. Integrated Wealth Concepts LLC grew its stake in Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after acquiring an additional 30 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in Waters by 5.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock worth $189,000 after purchasing an additional 35 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in Waters by 13.1% in the 2nd quarter. Penserra Capital Management LLC now owns 327 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 38 shares during the period. Tokio Marine Asset Management Co. Ltd. boosted its holdings in Waters by 1.8% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock valued at $679,000 after purchasing an additional 41 shares during the period. Finally, Clearstead Advisors LLC grew its position in shares of Waters by 7.5% during the 3rd quarter. Clearstead Advisors LLC now owns 586 shares of the medical instruments supplier’s stock valued at $176,000 after purchasing an additional 41 shares in the last quarter. 94.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating and issued a $440.00 price target on shares of Waters in a report on Tuesday, February 10th. UBS Group dropped their price objective on Waters from $395.00 to $370.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Wall Street Zen lowered Waters from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Robert W. Baird set a $363.00 price target on Waters in a report on Tuesday, February 10th. Finally, Barclays initiated coverage on Waters in a research report on Tuesday, February 10th. They set an “overweight” rating and a $400.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $393.84.

Waters Price Performance

Shares of NYSE WAT traded up $1.98 during trading hours on Friday, reaching $285.30. 70,827 shares of the stock traded hands, compared to its average volume of 1,089,514. The company’s 50-day simple moving average is $354.58 and its two-hundred day simple moving average is $350.90. The company has a market capitalization of $27.99 billion, a P/E ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 1.20. Waters Corporation has a 52-week low of $275.05 and a 52-week high of $414.15. The company has a quick ratio of 1.27, a current ratio of 1.73 and a debt-to-equity ratio of 0.37.

Waters (NYSE:WAT) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, beating analysts’ consensus estimates of $4.50 by $0.03. The business had revenue of $932.36 million for the quarter, compared to analysts’ expectations of $928.17 million. Waters had a net margin of 20.30% and a return on equity of 34.79%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the business earned $4.10 earnings per share. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Equities research analysts forecast that Waters Corporation will post 12.86 EPS for the current year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.